This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
== Ocean pollution == A Wall Street Journal report on ocean pollution, specifically, "Annual metric tonnes of mismanaged plastic waste in global waters", identified the top 12 polluting nations as of 2010. China was number one, Thailand at number seven, tied with Egypt. Five ASEAN nations were among the 12: Indonesia, 2; Philippines, 3; Vietnam, 4; Thailand, 7; Malaysia, 8.
There are a variety of career paths within the field of medical genetics, and naturally the training required for each area differs considerably. The information included in this section applies to the typical pathways in the United States and there may be differences in other countries. US practitioners in clinical, counseling, or diagnostic subspecialties generally obtain board certification through the American Board of Medical Genetics.
As with any other organic compound, it is prudent to characterize synthetic oligonucleotides upon their preparation. In more complex cases (research and large scale syntheses) oligonucleotides are characterized after their deprotection and after purification. Although the ultimate approach to the characterization is sequencing, a relatively inexpensive and routine procedure, the considerations of the cost reduction preclude its use in routine manufacturing of oligonucleotides. In day-by-day practice, it is sufficient to obtain the molecular mass of an oligonucleotide by recording its mass spectrum. Two methods are currently widely used for characterization of oligonucleotides: electrospray mass spectrometry (ESI MS) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). To obtain informative spectra, it is very important to exchange all metal ions that might be present in the sample for ammonium or trialkylammonium [e.c. triethylammonium, (C2H5)3NH+] ions prior to submitting a sample to the analysis by either of the methods.
=== Other indications === Sertraline is approved for the treatment of post-traumatic stress disorder (PTSD). The UK's National Institute for Clinical Excellence recommends it for patients who prefer drug treatment to a psychological one. Other guidelines also suggest sertraline as a first-line option for pharmacological therapy. When necessary, long-term pharmacotherapy can be beneficial. There are both negative and positive clinical trial results for sertraline, which may be explained by the types of psychological traumas, symptoms, and comorbidities included in the various studies. Positive results were obtained in trials that included predominantly women (75%) with a majority (60%) having physical or sexual assault as the traumatic event. Somewhat contrary to the above suggestions, a meta-analysis of sertraline clinical trials for PTSD found it to be statistically superior to placebo in the reduction of PTSD symptoms but the effect size was small. Another meta-analysis relegated sertraline to the second line, proposing trauma focused psychotherapy as a first-line intervention. The authors noted that Pfizer had declined to submit the results of a negative trial for inclusion in the meta-analysis, making the results unreliable. Sertraline, when taken daily, can be useful for the treatment of premature ejaculation. A disadvantage of sertraline is that it requires continuous daily treatment to delay ejaculation significantly.
The form of government is a democratic federative republic, with a presidential system, as decided in a 1993 referendum. The president is both head of state and head of government of the Union and is elected for a four-year term, with the possibility of re-election for a second successive term. The current president is Luiz Inácio Lula da Silva. The president appoints the Ministers of State, who form the cabinet and assist in government.
Sources: en.wikipedia.org
The word theory in "the theory of evolution" does not imply scientific doubt regarding its validity; the concepts of theory and hypothesis have specific meanings in a scientific context. While theory in colloquial usage may denote a hunch or conjecture, a scientific theory is a set of principles that explains an observable phenomenon in natural terms. Scientific facts and theories are not mutually exclusive, and evolution is a theory in the same sense as germ theory or the theory of gravitation. The theory of evolution does not attempt to explain the origin of life or the origin and development of the universe. The theory of evolution deals primarily with changes in successive generations over time after life has already originated. The scientific model concerned with the origin of the first organisms from organic or inorganic molecules is known as abiogenesis, and the prevailing theory for explaining the early development of the universe is the Big Bang model. Evolution is not a progression from inferior to superior organisms, and it also does not necessarily result in an increase in complexity. Evolution through natural selection only causes successive generations of a population of organisms to become more fit for their environment than previous generations. A population can evolve to become simpler or to have a smaller genome, and atavistic ancestral genetic traits can reappear after having been lost through evolutionary change in previous generations.
== Function == During swallowing, the soft palate and the uvula move together to close off the nasopharynx, and prevent food from entering the nasal cavity. It has also been proposed that the abundant amount of thin saliva produced by the uvula serves to keep the throat well lubricated. It has a function in speech as well. In many languages, a range of consonant sounds, known as uvular consonants, are articulated by creating a constriction of airflow between the uvula and the back of the tongue. The voiced uvular trill, written [ʀ] in the International Phonetic Alphabet, is one example; it is used in French, Arabic and Hebrew, among other languages. It has been suggested that the uvula is an accessory speech organ. Stimulation of the uvula also causes the gag reflex to initiate. This is often a problem for people with uvula piercings, and a common method of inducing vomiting. It also acts as a food sensor/guard that aids in breathing between mouthfuls, stopping small pieces of food from being inhaled, leading to choking.
== Metabolism == Studies of the metabolism of synephrine by monoamine oxidases derived from rat brain mitochondria showed that synephrine was a substrate for deamination by both MAO-A and MAO-B, with Km = 250 μM and Vmax = 32.6 nM/mg protein/30 minutes; there was some evidence for preferential deamination by MAO-A.
Albert Pike lost confidence in Cassard's performance. In 1861, he sent another Cuban named Vicente Antonio de Castro back to Cuba to take over and "...regularize any error that Andres Cassard might have committed in organizing the bodies of Cuba, and to establish that peace and harmony that should exist among the ancients in the Ancient and Accepted Scottish Rite." Albert Pike and the Grand Lodge of South Carolina became increasingly embroiled in the American Civil War. Pike served as a General in the Confederate States Army, and de Castro began acting more autonomously. Instead of withdrawing from Freemasonry, however, Pike sought to make Confederate South Carolina the epicentre of the entire Masonic world. de Castro, when he observed the currents within Colon Freemasonry, saw that even though the Grand Lodge and the Supreme Council disagreed on much of the issues in society, they were mostly led by Spanish loyalists desiring that Spain remain a part of Cuba's future. Historians note the discord, because before the Civil War, Albert Pike had long been a proponent of Manifest destiny and a soldier in the Westward Expansion – but the Lodges he created were still loyal to Spain. Still at the forefront of the debate was the institution of slavery. On March 28, 1862, instead of co-organizing with the Colon bodies, de Castro created an entirely new body called the Supremo Consejo y Gran Oriente de Cuba y Las Antillas (GOCA) (English: Supreme Council and Grand Orient of Cuba and the Antilles).
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。